Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Companies

Set Alert for Companies

Dermavant Prepares For First Launch, Looking To Build A Blockbuster Psoriasis Brand

The Roivant-owned company's Vtama topical cream was approved by the US FDA with a broad label permitting use for mild, moderate or severe psoriasis.

Approvals Launches

Vertex Spots Potential Bargain Of $60m Entry Into Complement Regulation

Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.

Deals Ophthalmic

Idorsia And J&J Hypertension Drug Edges Closer To An Uncertain Market

The partners released positive data from a Phase III study of their resistant hypertension drug candidate, aprocitentan, and have already started talks with regulators, but its commercial prospects remain uncertain.

Clinical Trials Cardiovascular

Zymeworks Rejects ‘Opportunistic’ Investor Takeover Bid

Activist investor All Blue wants to mount a takeover, but the biotech’s board is holding out for encouraging pipeline news to help fight off the bid.

Companies Commercial

Stock Watch: Biotech’s Commercial Laggards Drag On Sector

Some commercial-stage biotechnology companies blame the pandemic for their declining sales and continued losses. While an acquisition by a bigger company might once have been an aspiration, further fundraisings seem to be the more likely outcome.

Stock Watch Commercial

Korean Biopharmas Rush To Boston: What Are The Challenges And Opportunities?

The head of the US arm of a major Korean government development institute talks to Scrip about why biotechs and pharma firms are flocking to Boston, how the organization is providing support and what the main challenges are.

South Korea Business Strategies

Stada Poised To Launch As Calliditas Finally Wins EU Nod For Kinpeygo

The Swedish biotech’s patience paid off as it received a positive EU CHMP opinion on its rare nephrology drug Kinpeygo, known elsewhere as Tarpeyo, following delays related to manufacturing questions.

Approvals Renal

Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck

Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.

Companies Deals

Small Molecules Attract Investors As Two Chinese Biotechs Bag $161m

Jiangsu Hengrui subsidiary Reistone and Shanghai Laekna raise a combined $161m for their innovative candidates.

China Financing

Agios CEO Fouse On Building A Sustainable Business Model

In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.

Business Strategies Companies

Bavarian Nordic Rises As It Meets Demand For Monkeypox Vaccine

The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.

Commercial Companies
See All
UsernamePublicRestriction

Register